Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03698331 · ClinicalTrials.gov registry record · Phase 4
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
A Phase 4 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT03698331 is a Phase 4 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 89 participants.
The verdict
NCT03698331, a Phase 4 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
Interventions
- DRUG Placebo oral capsule
- DRUG Valbenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03698331
The ClinicalTrials.gov registry entry for NCT03698331 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03698331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03698331 about?
NCT03698331 is a clinical study titled "The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine". This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
What is the current status of trial NCT03698331?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2018-09-14. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT03698331?
The interventions under investigation include: Placebo oral capsule (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT03698331?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.